COMPREHENSIVE
MEDICINAL CHEMISTRY II

Editors-in-Chief
Dr John B Taylor
Former Senior Vice-President for Drug Discovery, Rhône-Poulenc Rorer, Worldwide, UK

Professor David J Triggle
State University of New York, Buffalo, NY, USA

Volume 1
GLOBAL PERSPECTIVE

Volume Editor
Dr Peter D Kennewell
Swindon, UK
Contents

Contents of all Volumes xi
Preface xix
Preface to Volume 1 xxi
Editors-in-Chief xxiii
Editor of Volume 1 xxiv
Contributors to Volume 1 xxv

Historical Perspective and Outlook

1.01 Reflections of a Medicinal Chemist: Formative Years through Thirty-Seven Years Service in the Pharmaceutical Industry
R F HIRSCHMANN, University of Pennsylvania, Philadelphia, PA, USA and
J L STURCHIO, Merck & Co., Inc., White House Station, NJ, USA

1.02 Drug Discovery: Historical Perspective, Current Status, and Outlook
P W ERHARDT, University of Toledo, OH, USA and J R PROUDFOOT, Boehringer Ingelheim Inc., Ridgefield, CT, USA

1.03 Major Drug Introductions
P D KENNEWELL, Swindon, UK

The Impact of New Genomic Technologies

1.04 Epigenetics
W W WEBER, University of Michigan, Ann Arbor, MI, USA

1.05 Personalized Medicine
D GURWITZ, Tel-Aviv University, Tel-Aviv, Israel and V G MANOLOPOULOS, Democritus University of Thrace, Alexandroupolis, Greece

1.06 Gene Therapy
M THANOU, Imperial College London, London, UK, and S WADDINGTON, University College London, London, UK, and A D MILLER, Imperial College London, London, UK
## Sources of New Drugs

1.07 Overview of Sources of New Drugs  
D BROWN, *Alchemy Biomedical Consulting, Cambridge, UK*

1.08 Natural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals  
G M CRAGG and D J NEWMAN, *NCI, Frederick, MD, USA*

1.09 Traditional Medicines  
L A MITSCHER, *University of Kansas, Lawrence, KS, USA*

1.10 Biological Macromolecules  
J K OSBOURN, *Cambridge Antibody Technology, Cambridge, UK*

1.11 Nutraceuticals  
P A LACHANCE and Y T DAS, *Rutgers – The State University of New Jersey, New Brunswick, NJ, USA*

## Animal Experimentation

1.12 Alternatives to Animal Testing  
R D COMBES, *FRAME, Nottingham, UK*

## The Role of Industry

1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery  
C G NEWTON, *BioFocus DRI, Saffron Walden, UK*

1.14 The Role of the Pharmaceutical Industry  
R BARKER, *Association of the British Pharmaceutical Industry (ABPI), London, UK*  
and M DARNBROUGH, *London, UK*

1.15 The Role of the Venture Capitalist  
D J BOWER, *University of Dundee, Scotland, UK*

1.16 Industry–Academic Relationships  
M DARNBROUGH, *London, UK* and M SKINGLE, *GlaxoSmithKline, Stevenage, UK*

## Drug Discovery: Revolution, Decline?

1.17 Is the Biotechnology Revolution a Myth?  
M M HOPKINS, *University of Sussex, Brighton, UK*, and A KRAFT and  
P A MARTIN, *Nottingham University, Nottingham, UK*, and P NIGHTINGALE and  
S MAHDI, *University of Sussex, Brighton, UK*

1.18 The Apparent Declining Efficiency of Drug Discovery  
D TRIST, E RATTI, and L DA ROS, *GlaxoSmithKline, Verona, Italy*

## Healthcare in the Social Context

1.19 How Much is Enough or Too Little: Assessing Healthcare Demand in Developed Countries  
D CALLAHAN, *The Hastings Center, Garrison, NY, USA*

1.20 Health Demands in Developing Countries  
A A WASUNNA, *The Hastings Center, Garrison, NY, USA*

1.21 Orphan Drugs and Generics  
C-P MILNE and L A CABANILLA, *Tufts University, Boston, MA, USA*
Ethical Issues

1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment 681

1.23 Ethical Issues and Challenges Facing the Pharmaceutical Industry 709
M L EATON, Stanford University, Graduate School of Business, Stanford, CA, USA

Funding and Regulation of Research

1.24 The Role of Government in Health Research 725
J K OZAWA, SRI International, Arlington, VA. USA and Q C FRANCO, StratEdge, Washington, DC, USA

1.25 Postmarketing Surveillance 755
A LI WAN PO, Centre for Evidence-Based Pharmacotherapy, Nottingham, UK

Intellectual Property

1.26 Intellectual Property Rights and Patents 779
J COCKBAIN, Frank B Dehn & Co, Oxford, UK

Subject Index 817